Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)

Historic Finished Goods for Harmony Biosciences Holdings (HRMY) over the last 2 years, with Q4 2024 value amounting to $2.8 million.

  • Harmony Biosciences Holdings' Finished Goods rose 2111.26% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year increase of 2111.26%. This contributed to the annual value of $2.8 million for FY2024, which is 2111.26% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Finished Goods of $2.8 million as of Q4 2024, which was up 2111.26% from $3.3 million recorded in Q3 2024.
  • Harmony Biosciences Holdings' Finished Goods' 5-year high stood at $3.3 million during Q3 2024, with a 5-year trough of $2.3 million in Q4 2023.